Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivities01:30

Hypersensitivities

556
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
556
Allergic Reactions02:06

Allergic Reactions

27.3K
Overview
27.3K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

246
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
246
Allergic Drug Reactions01:27

Allergic Drug Reactions

821
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
821

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus.

Dermatitis : contact, atopic, occupational, drug·2026
Same author

Practical Techniques: Photopatch Testing.

Dermatitis : contact, atopic, occupational, drug·2026
Same author

Acrylate Copolymers/Crosspolymers in Sunscreens: Minimally Allergenic, Without Evidence of Need for Avoidance by (Meth)Acrylate-Sensitized Individuals.

Contact dermatitis·2026
Same author

Long-term disability outcomes in Hansen's disease: A 20-year comparative study of Lepromatous vs. Tuberculoid Leprosy.

PLoS neglected tropical diseases·2026
Same author

Response to Pak et al., "Regulatory Gaps in Sunscreen Approval: A Comparison of U.S. and Korean UV Filters." Sunscreen Regulatory Update: Approval of Bemotrizinol by the US FDA.

Journal of the American Academy of Dermatology·2026
Same author

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial.

Dermatology and therapy·2026
Same journal

Black Dots on the Scalp of a Child.

Cutis·2026
Same journal

Psoriasis and Obesity: A Clinical Review of the Bidirectional Link and Management Implications.

Cutis·2026
Same journal

Adalimumab in Lichen Planus: A Narrative Review of Treatment and Paradoxical Reactions.

Cutis·2026
Same journal

The Future of Psoriasis Care.

Cutis·2026
Same journal

Evaluating GPT-4o for Automated Classification of Skin Lesions Using the HAM10000 Dataset.

Cutis·2026
Same journal

Metastatic Primary Extramammary Paget Disease: A Case Series.

Cutis·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.4K

Simplifying Allergic Contact Dermatitis Management with the Contact Allergen Management Program 2.0.

Sarah Kamsiah Zemlok1, Solbie Choi1, Amber R Atwater1

  • 1Sarah Kamsiah Zemlok is from the University of Connecticut School of Medicine, Farmington. Sarah Kamsiah Zemlok also is from and Dr. Yu is from the Department of Dermatology, Massachusetts General Hospital, Boston. Solbie Choi is from the Albert Einstein College of Medicine, Bronx, New York. Dr. Atwater is from Distinctive Dermatology, Vienna, Virginia, and the Department of Dermatology, George Washington University, Washington, DC. Dr. Reeder is from the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison. Dr. Adler is from the Department of Dermatology, Keck School of Medicine, Los Angeles, California.

Cutis
|May 20, 2025
PubMed
Summary
This summary is machine-generated.

Managing allergic contact dermatitis (ACD) requires strategic allergen avoidance. The Contact Allergen Management Program (CAMP) 2.0 offers enhanced guidance for patients and physicians, improving quality of life.

More Related Videos

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

2.7K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.3K

Related Experiment Videos

Last Updated: Jun 13, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.4K
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

2.7K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.3K

Area of Science:

  • Dermatology
  • Allergology
  • Public Health

Background:

  • Allergic contact dermatitis (ACD) presents significant management challenges for patients.
  • Effective allergen avoidance is crucial but often difficult for individuals.
  • Physician awareness of patient challenges and long-term strategies is essential.

Purpose of the Study:

  • To highlight the role of contact allergen databases in ACD management.
  • To introduce the updated Contact Allergen Management Program (CAMP) 2.0.
  • To demonstrate how CAMP 2.0 and product databases can optimize patient outcomes.

Main Methods:

  • Review of the updated CAMP 2.0 features.
  • Discussion of strategies for utilizing contact allergen databases.
  • Analysis of how these tools support patient education and self-management.

Main Results:

  • CAMP 2.0 provides enhanced resources for self- and physician-directed guidance.
  • Product database tools aid in optimizing patient outcomes for ACD.
  • Improved quality of life for patients with ACD is a key benefit.

Conclusions:

  • Contact allergen databases are vital for patient education and ACD management.
  • CAMP 2.0 is a valuable resource for improving patient quality of life.
  • Utilizing updated tools like CAMP 2.0 enhances ACD care and outcomes.